In this review:
EORTC 1333/PEACE-3: final OS results of radium-223 + enzalutamide in mCRPC
BRCAAway: abiraterone + olaparib in mCRPC with DNA repair defects
POSEIDON: hormone therapy + post-operative radiotherapy in recurrent prostate cancer
KEYNOTE-B15: enfortumab vedotin + pembrolizumab in cisplatin-eligible MIBC
Disitamab vedotin in HER2-expressing, pre-treated urothelial cancer
RETAIN-1/2: ctDNA to guide bladder preservation in MIBC
IMvigor011: ctDNA-guided atezolizumab in MIBC
CLIMATE: miR-371 as a marker of MRD in stage 1 testicular germ cell tumours
LITESPARK-011: belzutifan + lenvatinib in advanced RCC after anti-PD-1/L1
LITESPARK-022: belzutifan + pembrolizumab in clear cell RCC
A first-in-human, dual-masked T-cell engager targeting PSMA & CD3 in latestage mCRPC
Please login below to download this issue (PDF)